Key facts
- This page summarizes Ian Harvey Zwicker's Form 4 filing for Emmaus Life Sciences, Inc. (EMMA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Feb 2024, 16:40.
Ian Harvey Zwicker - 01 Feb 2024 Form 4 Insider Report for Emmaus Life Sciences, Inc. (EMMA)
- Reporting relationship
- Director
- Issuer ticker
- EMMA
- Reported as of
- 01 Feb 2024
- Net transaction value
- +$15,000
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2024, 16:40:23 UTC
- Prior SEC filing
- 17 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- Ian Zwicker
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ian Harvey Zwicker filed Form 4 for Emmaus Life Sciences, Inc. (EMMA) on 05 Feb 2024.
Change
- Previous filing in this sequence was filed on 17 Jan 2023.
- Current net transaction value: +$15,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EMMA
transaction
Derivative
Options
Award
- Transaction value
- $15,000
- Shares
- +100,000
- Change %
- Price
- $0.1500
- Shares after
- 100,000
- Date
- 01 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $0.1500
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest in four equal installments as of the last day of each quarter beginning on March 31, 2024